Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of ANG-3070 in Idiopathic Pulmonary Fibrosis
NCT05387785Phase 1Unknown
- Sponsor
- Angion Biomedica Corp.
- Start
- Jun 2022
- Primary completion
- Nov 2022
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial of ansornitinib in idiopathic pulmonary fibrosis (IPF) (4 arms), sponsored by Angion Biomedica Corp. Primary endpoints: Treatment-Emergent Adverse Events at Day 30, Treatment-Emergent Adverse Events from ECGs at Day 30 and 2 more. Status: unknown.
02
Drugs
ansornitinib
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT05387785.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05387785.